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Food Biotechnology: A Legal Perspective-U.S. Regulation Panel
PANEL REMARKS ON REGULATING GENETICALLY
MODIFIED FOODS IN THE UNITED STATES
Participants: L. Val Giddings, Gregory Jaffe & David Hegwood
Moderated by Kathleen Hart
Cite as: L. Val Giddings, et al., Symposium: Panel Remarks on Regulating Genetically
Modiﬁed Foods in the United States, 10 RICH J.L. & TECH. 11 (2003), at http://law.richmond.
edu/jolt/v10i2/article11.pdf.
Ms. Kathleen Hart:

{1} Thank you all. In my opinion, containment of pharmaceutical GM crops
is essential and hard to do. The USDA just recently came up with some new
guidelines for genetically modiﬁed pharm plants, but how can the public
have an input into what’s going on if they don’t even know where the crops
are growing, or what’s in the crops, because this is protected as conﬁdential
business information? Should the public have a say? How would we
accomplish--giving the public a say about whether they want genetically
engineered wheat, even aside from the export issues. Third, I understand GE
salmon is very close to being approved and released. That’s a containment
issue of another kind. The fourth issue is that there are all kinds of organisms
that don’t even fall under EPA, USDA, or FDA jurisdiction, such as GE
mosquitoes, and so forth. So, is there some way that you would want to propose
changes to the regulations that would help bring the public into the debate? A
couple minutes each.

Mr. Gregory Jaffe:

{2} Well I’m not going to tackle all those, it’s too much, but my view on
transparency and public participation is that regulatory processes should be
open. I do also believe that there is genuine conﬁdential business information.
To the extent that some information is genuine conﬁdential business
information and qualiﬁes under the case law that exists out there, it should be
protected. In some cases that may be the test plot where something is grown.
That doesn’t mean you couldn’t ﬁnd out the state it’s grown in or the county it’s
grown in; that might not be conﬁdential.
{3} Similarly, in some cases the drug or the speciﬁc product may be
conﬁdential. A lot of these things are patented; a lot of those things are out
there. One of the things about something being conﬁdential business
information is that it’s the traits you get from the company that are protected.
My criticism of the system is that I think the government has taken at face value
a lot of the companies’ claims of CBI. The way the system is supposed to work,
the government is supposed to question those and only protect what is truly
conﬁdential.
{4} My answer to your question is, if information is truly conﬁdential then,
yes, the company should have a right to keep it conﬁdential, but the agency
should be looking closely at that and they should be doing it based on the case
law that exists out there. As to your other remarks, such as about the wheat,
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I agree with David Hegwood. Our regulatory system and agencies like FDA
should deal with risks; they should deal with the food safety risks. That’s what
we want them to do, be an independent agency that looks at the risks.
{5} Other social issues, marketing issues, other kinds of things, I agree that
those are big concerns and they should be addressed but they shouldn’t be
addressed by regulatory agencies that are addressing safety concerns. I don’t
think you should mix jurisdictions. I think one of the things that our society has
to ﬁgure out through Congress and the Administration is, what are the forums to
address those other social, ethical, or other factors? I’m one who’s not advocating
FDA to step in to do that.
Mr. David Hegwood: {6} Well, I will brieﬂy address the issue of pharmaceutical ﬁeld trials. I think
the ﬁrst point to emphasize is these are ﬁeld trials. This is research and
development. These are not commercialized products. These are not products
that humans are going to consume. This is strictly research and development at
this stage. So if the public is saying, “We want to know where these are grown
and what they are,” I guess I would have to ask “Why do you want to know?”
Is it because you’re afraid you’re going to be consuming them? If you are, I
can tell the answer is no, you’re not. The objective of our regulatory system
is to ensure that you don’t consume the goods. That’s the whole purpose. So, at
some point should there be public input into the process before these things
are commercialized, if and when they are ever commercialized? Absolutely,
and it will happen. The process is in place, that’s what the regulations say.
Again, as Greg Jaffe said, you have to respect the conﬁdential information. This
is not a new issue; this is something we’ve been dealing with for as long as we’ve
had business.
Dr. Val Giddings:

{7} Yes, I’d like to take all of the questions, but I’m not sure I can remember
them all. First, I’ll point out that it is not true that we don’t know where these
things are being grown. Conﬁdential business information sometimes protects
the speciﬁc cooperator and the individual farmer who is growing these crops,
but even when that claim is made, the county in which this is grown is speciﬁed
several places in the environmental assessment by the companies in each and
every request for permission to grow this stuff. This is on record; you don’t have
to believe me. Go to the USDA website, and you can download these tables.
You can spend the rest of your natural life, or a good portion of it, downloading
and reviewing this information.
{8} On to the salmon issue and containment. Dr. Hoover has said there have
not been any surprises to date on the transgenic crops produced for food use and
so forth – and that’s true. He did see, however, assert a surprise with the salmon.
The one surprise that has come up with this transgenic salmon, after extensive
analysis, has been that it contains a slightly higher yet signiﬁcant concentration of
the omega three fatty acids that has everyone encouraged to eat salmon. The only
surprises that I know of so far have been positive surprises.
{9} On the issue of containment, the transgenic salmon that are being developed
are number one, all female, and number two, sterile. Okay, so these salmon, even
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if they are put in commerce, and even if they are released in ocean pens which
is conventional today, these salmon represent a substantial and signiﬁcant
improvement in the level of safety over and above what we already see with the
existing salmon farming technologies.
{10} So that highlights on a very important question to focus on when we’re
talking about safety of crops and foods. The right question to ask isn’t how safe
is it or what is the level of safety in terms what probabilities or consequence
A, B, or C. The question that is really most useful to ask is how does the level
of safety for this new product compare to the level of safety that we already
accept as routine with the existing products? Without exception, in each and
every case to date, the answer to that question for crops and foods produced by a
biotech method are at least as safe and in numerous cases they are safer
than those that we already now enjoy.
Ms. Kathleen Hart:

{11} Thank you all for your participation.
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